Online citations, reference lists, and bibliographies.
← Back to Search

Editorial: Emerging Therapies For Malignant Mesothelioma

Nico van Zandwijk, G. Reid, P. Baas
Published 2020 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1093/annonc/mdy195
Pleural mesothelioma: is the surgeon still there?
I. Opitz (2018)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1016/S1470-2045(11)70307-2
The MARS feasibility trial: conclusions not supported by data.
W. Weder (2011)
10.1002/(SICI)1097-0142(19990801)86:3<546::AID-CNCR28>3.0.CO;2-G
Intrapleural administration of interleukin‐2 for the treatment of patients with malignant pleural mesothelioma
T. Karrison (1999)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1016/S1470-2045(18)30100-1
Novel therapies for malignant pleural mesothelioma.
A. Scherpereel (2018)
10.3892/IJO.6.2.431
Natural-killer cell-mediated cytotoxicity of blood-lymphocytes from patients with malignant mesothelioma treated by intrapleural interleukin-2.
P. Astoul (1995)
a randomised, controlled, open-label, phase 3 trial
G Zalcman (2016)
a first-in-man, phase 1, open-label, dose-escalation study
N van Zandwijk (2017)
10.1158/2159-8290.CD-18-0804
Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Julija Hmeljak (2018)
[Phase II study].
H. Niitani (1995)
10.1002/1097-0142(19910415)67:8<2033::AID-CNCR2820670804>3.0.CO;2-8
Activity of intrapleural recombinant gamma‐interferon in malignant mesothelioma
C. Boutin (1991)
10.1136/bmj.310.6971.57b
Conclusions not supported by data
J. Temple (1995)
10.1016/S1470-2045(17)30621-6
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
N. van Zandwijk (2017)
10.1200/JCO.2016.66.7931
Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.
N. Hanna (2016)
10.1038/ng.3520
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
R. Bueno (2016)
10.1002/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N
Intrapleural treatment with recombinant gamma‐interferon in early stage malignant pleural mesothelioma
C. Boutin (1994)
10.1016/j.athoracsur.2017.09.036
National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study.
Sahar A Saddoughi (2018)



Semantic Scholar Logo Some data provided by SemanticScholar